Pavía RN, Juárez J, Miño LG, Soffe PJ, Drummond T, Erazo K, Porras Ó, Ivankovich G, Estripeaut D, Luciani K, Morales PDM, Muñoz HR, Pérez MÁ, Prieto TLM, Navarro GML, Castaneda VLG

Language: Spanish
References: 9
Page: 106-111
PDF size: 358.44 Kb.

ABSTRACT

PLANTAIDS network, of the Ibero-American Program of Science and Technology for Development (CYTED), is a collaboration between researchers from nine Latin American countries and different institutions around the world focused on the fight against human immunodeficiency virus (HIV) infection in children: Spanish Cohort of HIV-Infected Children and Adolescents (CoRISpe), Italian-Latin American Institute (IiLA), Pediatric European Network for Treatment of AIDS (PENTA) and ESTHER Program of the Spanish Ministry of Health. In the year 2023, members of this network coordinated the PLANTAIDS guidelines to provide evidence-based and/or expert recommendations for all those professionals involved in care of children and adolescents living with HIV in Latin America. This article outlines the recommendations for the transition from the previous antiretroviral regimens to the new regimens based on integrase inhibitors, mainly dolutegravir, which have been proven to be more effective, easier to take and has fewer side effects than alternative drugs that are currently used.

REFERENCES

1. Hernanz-Lobo A, Ruiz Saez B, Carrasco García I, Mino-Leon G, Juárez J, Pavía Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infect Dis. 2022; 22 (1): 347. doi: 10.1186/s12879-022-07311-8.

2. Organización Mundial de la Salud. Transición hacia los nuevos antirretrovirales en los programas contra el VIH: consideraciones clínicas y programáticas. OMS, 2017. [Consultado el 24 de marzo 2023] Disponible en: https://iris.paho.org/bitstream/handle/10665.2/51822/OPSCDE18048_spa.pdf?sequence=1&isAllowed=y

3. Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Med. 2021; 385 (27): 2531-2543. doi: 10.1056/NEJMoa2108793.

4. Bacha JM, Dlamini S, Anabwani F, Gwimile J, Kanywa JB, Farirai J et al. Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in eastern and Southern Africa. Pediatr Infect Dis J. 2023; 42 (7): 576-581. doi: 10.1097/INF.0000000000003878.

5. Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022; 9 (9): e638-e648. doi: 10.1016/S2352-3018(22)00163-1.

6. Panel on antiretroviral therapy and medical management of children living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. [Consulted 15 April 2023] Available in: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new

7. Sociedad Española de Infectología Pediátrica. Documento de consenso sobre tratamiento antirretroviral en niños y adolescentes con infección por el virus de la inmunodeficiencia humana. 2022. [Consultado el 15 de abril de 2023] Disponible en: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/2022/guias_TAR_ninos_enero_2022_def.pdf

8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359 (21): 2233-2244. doi: 10.1056/NEJMoa0800971.

9. Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR et al. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022; 9 (9): e627-e637. doi: 10.1016/S2352-3018(22)00160-6.